|Day Low/High||4.42 / 4.68|
|52 Wk Low/High||35.72 / 80.00|
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
When you seek to find the right structure or combination, you can get hurt.
The Dow posts a record close with the S&P 500 lower, while tech stocks dragged on the Nasdaq as Wall Street looks to a Fed decision on interest rates Tuesday.
The Dow rises but pares gains as Wall Street looks to a Fed decision on interest rates later in the week.
Levi & Korsinsky, LLP announces that it has commenced an investigation of Ophthotech Corporation ("Ophthotech" or the "Company") (NASDAQ:OPHT) concerning possible violations of federal securities laws by the Company...
Here's a technical look on how to trade some of the most active stocks on the market this week.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Stocks are mixed Monday as oil prices surge after non-OPEC countries agree to cut production and markets anticipate Fed moves.
Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.
Shares of Ophthotech are plunging after the company's Phase 3 results failed to meet specific endpoints.
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating...
Investors in Ophthotech Corp saw new options become available today, for the January 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Ophthotech Corporation (Nasdaq: OPHT) today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company's business and product development programs.
Ophthotech Corporation (Nasdaq:OPHT) today announced that the Phase 2b study results of Fovista ® (pegpleranib), the Company's anti-PDGF agent administered in combination with Lucentis ® (ranibizumab) anti-VEGF...
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter financial results on Tuesday, November 8, 2016.
Jim Cramer says he likes LUV and UAL, but JBLU is not a favorite.
Don't ignore a big shift for American Express and don't dig in your heels, says Jim Cramer.
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Stocks with insider trader activity include OPHT, MXIM and JBLU
Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the second quarter ended June 30, 2016 and provided an update on the Company's business and product development programs.
Ophthotech Corporation (Nasdaq:OPHT) today announced the election of Ian F.
The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 434,231 share increase in total short interest for Ophthotech Corp , to 2,977,494, an increase of 17.07% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2016 financial results on Wednesday, August 3, 2016.
Positive momentum and money flow set the stage for higher prices in these four stocks.
Ophthotech Corporation (Nasdaq: OPHT) today announced the completion of patient recruitment in its Phase 3 trial of Fovista ® (pegpleranib), anti-PDGF therapy, in combination with Eylea ® (aflibercept) or...
Stocks with insider trader activity include OPHT, MMS and MLNX